metabolic bone diseases research hub

A PHASE 1, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE AND MULTIPLE ASCENDING DOSE ESCALATION STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MES-1022 IN HEALTHY HUMAN SUBJECTS

This early-stage study is testing a new medicine called MES-1022 in healthy adults to see if it's safe and how it works in the body. It’s part of research into metabolic bone diseases affecting your bones, like osteoporosis. Participants will receive either the new medicine or a dummy treatment.